Roche Xeloda Gets Approved For Stomach Cancer In China
This article was originally published in PharmAsia News
Executive Summary
Shanghai Roche Pharmaceuticals has received China's State FDA approval for its targeting chemotherapy drug Xeloda (capecitabine) to treat progressive gastric cancer. Research data show that chemotherapy is an important approach for treating gastric cancer, especially for intermediate and advanced cancer. Xeloda is an oral chemotherapy drug first approved in the U.S. It was launched in 2001 for use in China for treating colorectal cancer and metastatic breast cancer. (Click here for more - Chinese Language)